Accéder au contenu
Merck

H0393

Hirudin

recombinant, expressed in unspecified host, ≥7,000 ATU/mg protein, powder

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

Numéro CAS:
UNSPSC Code:
12352202
NACRES:
NA.77
EC Number:
232-279-1
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Hirudin, recombinant, expressed in unspecified host, ≥7,000 ATU/mg protein (ATU = antithrombin units)

mol wt

~7 kDa

solubility

pyridine: soluble, water: soluble

recombinant

expressed in unspecified host

form

powder

specific activity

≥7,000 ATU/mg protein (ATU = antithrombin units)

shipped in

dry ice

storage temp.

−20°C

Quality Level

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

General description

The anticoagulant hirudin is a ~7 kDa acidic protein containing 65 amino acid residues. It occurs naturally in leeches (Hirudo medicinalis). It is the most potent natural inhibitor of both soluble and clot-bound thrombin. Hirudin binds thrombin with high affinity and covers more than 20% of the surface area of thrombin, occluding both the active site and exosite I (fibrinogen and PAR recognition site). This coverage blocks thrombus growth and platelet activation. Hirudin is not metabolized in the bloodstream of humans and is eliminated unchanged via kidney filtration. Native hirudin contains a sulfated tyrosyl residue (Tyr63), three disulfide bridges, and a high proportion of dicarboxylic acids. Hirudin is not glycosylated, and lacks tryptophan, arginine, and methionine residues. At least 20 isoforms have been identified and sequenced.
This recombinant hirudin product corresponds to the HV-1 variant sequence, with the exception that the Tyr63 residue is not sulfated.

Application

Antithrombotic efficacy by parenteral route is substantially prolonged by incorporation into cationic liposomes, which act as a sort of sustained-release device.

Preparation Note

Hirudin is soluble in water. The literature cites the use of "Dilution Fluid II" (35.7 mM acetic acid, 35.7 mM sodium diethyl barbiturate, 0.85% NaCl, 1% bovine serum albumin, and 0.5% PEG, pH 7.4) to dissolve hirudin (500 ATU/mL) and thrombin. Hirudin is reported to be soluble in pyridine, but practically insoluble in alcohol, ether, acetone, or benzene.

Analysis Note

Protein determined by Lowry.

Other Notes

One antithrombin unit (ATU) will neutralize one NIH unit of thrombin at 37 °C, based on direct comparison to an NIH thrombin reference standard.

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Hirudin as an inhibitor of thrombin.
Markwardt, F.
Methods in Enzymology, 19, 924-932 (1970)
[The reaction between hirudin and thrombin].
F MARKWARDT et al.
Hoppe-Seyler's Zeitschrift fur physiologische Chemie, 312(1-3), 85-98 (1958-01-01)
Hirudin and hirudin-based peptides.
S R Stone et al.
Methods in enzymology, 223, 312-336 (1993-01-01)
Jun Wang et al.
iScience, 25(3), 103971-103971 (2022-03-01)
Clotting Factor V (FV) is primarily synthesized in the liver and when cleaved by thrombin forms pro-coagulant Factor Va (FVa). Using whole blood RNAseq and scRNAseq of peripheral blood mononuclear cells, we find that FV mRNA is expressed in leukocytes, and
Serdar Duzgun et al.
Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India, 47(1), 102-108 (2014-07-06)
The effect of recombinant hirudin, which is the most powerful antithrombotic agent, on flaps with venous insufficiency was investigated. Oedema and congestion are frequent on flaps, causing necrosis unpredictably. Venous insufficiency and thrombosis are experimentally and clinically more frequent than

Contenu apparenté

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique